Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
R8ynqcPLyVTL2CtG
Listen
